555 related articles for article (PubMed ID: 26377465)
21. Mixed oligomers and monomeric amyloid-β disrupts endothelial cells integrity and reduces monomeric amyloid-β transport across hCMEC/D3 cell line as an in vitro blood-brain barrier model.
Qosa H; LeVine H; Keller JN; Kaddoumi A
Biochim Biophys Acta; 2014 Sep; 1842(9):1806-15. PubMed ID: 24997450
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic efficacy of stemazole in a beta-amyloid injection rat model of Alzheimer's disease.
Han M; Liu Y; Tan Q; Zhang B; Wang W; Liu J; Zhang XJ; Wang YY; Zhang JM
Eur J Pharmacol; 2011 Apr; 657(1-3):104-10. PubMed ID: 21316359
[TBL] [Abstract][Full Text] [Related]
23. Phorbol ester induced short- and long-term permeabilization of the blood-CSF barrier in vitro.
Angelow S; Zeni P; Höhn B; Galla HJ
Brain Res; 2005 Nov; 1063(2):168-79. PubMed ID: 16271356
[TBL] [Abstract][Full Text] [Related]
24. The Choroid Plexus in Healthy and Diseased Brain.
Kaur C; Rathnasamy G; Ling EA
J Neuropathol Exp Neurol; 2016 Mar; 75(3):198-213. PubMed ID: 26888305
[TBL] [Abstract][Full Text] [Related]
25. Global alterations to the choroid plexus blood-CSF barrier in amyotrophic lateral sclerosis.
Saul J; Hutchins E; Reiman R; Saul M; Ostrow LW; Harris BT; Van Keuren-Jensen K; Bowser R; Bakkar N
Acta Neuropathol Commun; 2020 Jun; 8(1):92. PubMed ID: 32586411
[TBL] [Abstract][Full Text] [Related]
26. Indoleamine-2,3-dioxygenase mediates neurobehavioral alterations induced by an intracerebroventricular injection of amyloid-β1-42 peptide in mice.
Souza LC; Jesse CR; Antunes MS; Ruff JR; de Oliveira Espinosa D; Gomes NS; Donato F; Giacomeli R; Boeira SP
Brain Behav Immun; 2016 Aug; 56():363-77. PubMed ID: 26965653
[TBL] [Abstract][Full Text] [Related]
27. Catalpol provides a protective effect on fibrillary Aβ
Liu C; Chen K; Lu Y; Fang Z; Yu G
Phytother Res; 2018 Jun; 32(6):1047-1055. PubMed ID: 29479743
[TBL] [Abstract][Full Text] [Related]
28. Matrix metalloprotease 8-dependent extracellular matrix cleavage at the blood-CSF barrier contributes to lethality during systemic inflammatory diseases.
Vandenbroucke RE; Dejonckheere E; Van Lint P; Demeestere D; Van Wonterghem E; Vanlaere I; Puimège L; Van Hauwermeiren F; De Rycke R; Mc Guire C; Campestre C; López-Otin C; Matthys P; Leclercq G; Libert C
J Neurosci; 2012 Jul; 32(29):9805-16. PubMed ID: 22815495
[TBL] [Abstract][Full Text] [Related]
29. MRZ-99030 - A novel modulator of Aβ aggregation: II - Reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice.
Rammes G; Gravius A; Ruitenberg M; Wegener N; Chambon C; Sroka-Saidi K; Jeggo R; Staniaszek L; Spanswick D; O'Hare E; Palmer P; Kim EM; Bywalez W; Egger V; Parsons CG
Neuropharmacology; 2015 May; 92():170-82. PubMed ID: 25637092
[TBL] [Abstract][Full Text] [Related]
30. Amyloid-β-induced matrix metalloproteinase-9 secretion is associated with retinal pigment epithelial barrier disruption.
Cao L; Wang H; Wang F
Int J Mol Med; 2013 May; 31(5):1105-12. PubMed ID: 23525277
[TBL] [Abstract][Full Text] [Related]
31. Amyloid-β peptide(1-40) elimination from cerebrospinal fluid involves low-density lipoprotein receptor-related protein 1 at the blood-cerebrospinal fluid barrier.
Fujiyoshi M; Tachikawa M; Ohtsuki S; Ito S; Uchida Y; Akanuma S; Kamiie J; Hashimoto T; Hosoya K; Iwatsubo T; Terasaki T
J Neurochem; 2011 Aug; 118(3):407-15. PubMed ID: 21585370
[TBL] [Abstract][Full Text] [Related]
32. Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy.
Hartz AM; Bauer B; Soldner EL; Wolf A; Boy S; Backhaus R; Mihaljevic I; Bogdahn U; Klünemann HH; Schuierer G; Schlachetzki F
Stroke; 2012 Feb; 43(2):514-23. PubMed ID: 22116809
[TBL] [Abstract][Full Text] [Related]
33. Functional and molecular characterization of the effect of amyloid-β42 on an in vitro epithelial barrier model.
Gheorghiu M; Enciu AM; Popescu BO; Gheorghiu E
J Alzheimers Dis; 2014; 38(4):787-98. PubMed ID: 24072066
[TBL] [Abstract][Full Text] [Related]
34. Choroid plexus dysfunction impairs beta-amyloid clearance in a triple transgenic mouse model of Alzheimer's disease.
González-Marrero I; Giménez-Llort L; Johanson CE; Carmona-Calero EM; Castañeyra-Ruiz L; Brito-Armas JM; Castañeyra-Perdomo A; Castro-Fuentes R
Front Cell Neurosci; 2015; 9():17. PubMed ID: 25705176
[TBL] [Abstract][Full Text] [Related]
35. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat.
Yang Y; Estrada EY; Thompson JF; Liu W; Rosenberg GA
J Cereb Blood Flow Metab; 2007 Apr; 27(4):697-709. PubMed ID: 16850029
[TBL] [Abstract][Full Text] [Related]
36. Alzheimer's disease-like pathology induced by amyloid-β oligomers in nonhuman primates.
Forny-Germano L; Lyra e Silva NM; Batista AF; Brito-Moreira J; Gralle M; Boehnke SE; Coe BC; Lablans A; Marques SA; Martinez AM; Klein WL; Houzel JC; Ferreira ST; Munoz DP; De Felice FG
J Neurosci; 2014 Oct; 34(41):13629-43. PubMed ID: 25297091
[TBL] [Abstract][Full Text] [Related]
37. Counteracting the effects of TNF receptor-1 has therapeutic potential in Alzheimer's disease.
Steeland S; Gorlé N; Vandendriessche C; Balusu S; Brkic M; Van Cauwenberghe C; Van Imschoot G; Van Wonterghem E; De Rycke R; Kremer A; Lippens S; Stopa E; Johanson CE; Libert C; Vandenbroucke RE
EMBO Mol Med; 2018 Apr; 10(4):. PubMed ID: 29472246
[TBL] [Abstract][Full Text] [Related]
38. Neurogenic effects of β-amyloid in the choroid plexus epithelial cells in Alzheimer's disease.
Bolos M; Spuch C; Ordoñez-Gutierrez L; Wandosell F; Ferrer I; Carro E
Cell Mol Life Sci; 2013 Aug; 70(15):2787-97. PubMed ID: 23455075
[TBL] [Abstract][Full Text] [Related]
39. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
Izzo NJ; Staniszewski A; To L; Fa M; Teich AF; Saeed F; Wostein H; Walko T; Vaswani A; Wardius M; Syed Z; Ravenscroft J; Mozzoni K; Silky C; Rehak C; Yurko R; Finn P; Look G; Rishton G; Safferstein H; Miller M; Johanson C; Stopa E; Windisch M; Hutter-Paier B; Shamloo M; Arancio O; LeVine H; Catalano SM
PLoS One; 2014; 9(11):e111898. PubMed ID: 25390368
[TBL] [Abstract][Full Text] [Related]
40. Lead Exposure in Developmental Ages Promotes Aβ Accumulation by Disturbing Aβ Transportation in Blood-Cerebrospinal Fluid Barrier/Blood-Brain Barriers and Impairing Aβ Clearance in the Liver.
Zhou CC; Wang XJ; Li ZC; Lu WJ; Zhang YT; Shen FM; Li DJ
Biol Trace Elem Res; 2022 Aug; 200(8):3702-3711. PubMed ID: 34787833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
